

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--|
| Name of entity | The Hydration Pharmaceuticals Company Limited |
| ABN | 620 385 677 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------|
| Name of Director | Adem Karafili |
| Date of last notice | 22 July 2022 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Ankara Holdings Pty Ltd <The Ankara Family Trust>* (Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.) |
| Date of change | 13 June 2023 |
| No. of securities held prior to change Ankara Holdings Pty Ltd <The Ankara Family Trust>* | 458,852 fully paid ordinary shares 448,437 fully paid ordinary shares subject to escrow until 13/06/2023 653,128 fully paid ordinary shares subject to escrow until 13/12/2023 74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject to escrow until 13/12/23 |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| <p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p> | <p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> • 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024; • 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and • 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026. <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p> |
| <p>Class</p> | <p>Fully Paid Ordinary Shares</p> |
| <p>Number acquired</p> | <p>Nil</p> |
| <p>Number disposed</p> | <p>Nil</p> |
| <p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p> | <p>Nil</p> |
| <p>No. of securities held after change</p> <p>Ankara Holdings Pty Ltd <The Ankara Family Trust>*</p> | <p>907,289 fully paid ordinary shares</p> <p>653,128 fully paid ordinary shares subject to escrow until 13/12/2023</p> <p>74,739 unlisted options with an exercise price of \$0.45 expiring on 13 January 2029 subject to escrow until 13/12/23</p> <p>The following unlisted options to acquire ordinary shares, all of which are subject to ASX escrow until 9 December 2023:</p> <ul style="list-style-type: none"> • 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024; • 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024; and • 1,000,000 unlisted options with an exercise price of \$0.29 expiring on 1 December 2026. |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| <p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p> | <p>53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027</p> |
| <p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>Release of fully paid ordinary shares from voluntary escrow.</p> |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|--|----|

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

For personal use only

+ See chapter 19 for defined terms.